# Liminatus Pharma, Inc.: overview LIMN · Nasdaq · CIK 1971387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/limn.md) · [Financials](/companies/limn/financials.md) · [Filings](/companies/limn/filings.md) · [Insiders](/companies/limn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.03)](/filings/0001104659-25-111651.md) | not reported | [(0.02)](/filings/0001104659-26-062734.md) | [0.00](/filings/0001104659-26-097304.md) | [(0.07)](/filings/0001104659-25-111651.md) | not reported | [(0.03)](/filings/0001104659-26-062734.md) | [(0.03)](/filings/0001104659-26-097304.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | [(387) d](/filings/0001104659-26-037933.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $k | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(0.20)](/filings/0001104659-26-037933.md) | [(0.43)](/filings/0001104659-26-037933.md) | | Free cash flow | $k | not reported | [(9,976)](/filings/0001104659-26-037933.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/limn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARISTEIA CAPITAL, L.L.C.](/funds/1080171.md) | 2026-06-30 | $16.3k | 319,510 | | Unchanged | | [Linden Advisors LP](/funds/1279396.md) | 2026-06-30 | $13.7k | 268,199 | | Unchanged | | [Saba Capital Management, L.P.](/funds/1510281.md) | 2026-06-30 | $11.9k | 233,761 | | Unchanged | | [MOORE CAPITAL MANAGEMENT, LP](/funds/1448574.md) | 2026-06-30 | $9.4k | 125,000 | | Unchanged | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $8.4k | 111,745 | | Unchanged | | [Polar Asset Management Partners Inc.](/funds/1326389.md) | 2026-06-30 | $6.3k | 122,688 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $5.3k | 70,616 | Call | Unchanged | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $2.9k | 83,353 | | Unchanged | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $2.6k | 35,100 | | Unchanged | | [LMR Partners LLP](/funds/1578621.md) | 2026-06-30 | $2.2k | 29,961 | | Unchanged | ## Recent filings [All 108 filings](/companies/limn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 05:15 ET | [8-K](/filings/0001104659-26-111665.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-111665 | | 2026-08-18 | 16:06 ET | [8-K](/filings/0001104659-26-098335.md) | 3.01 Delisting notice; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-098335 | | 2026-08-14 | 16:51 ET | [10-Q](/filings/0001104659-26-097304.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097304 | | 2026-08-04 | 16:30 ET | [8-K](/filings/0001104659-26-090423.md) | 5.07 Shareholder vote results | 0001104659-26-090423 | | 2026-07-30 | 21:49 ET | [8-K](/filings/0001104659-26-088380.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-088380 | | 2026-07-24 | 16:51 ET | [8-K](/filings/0001104659-26-086674.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-086674 | | 2026-07-14 | 17:36 ET | [SCHEDULE 13D/A](/filings/0001104659-26-083585.md) | Ownership report, active investor, amended | 0001104659-26-083585 | | 2026-07-13 | 08:43 ET | [DEF 14A](/filings/0001104659-26-082905.md) | Proxy statement, period 2026-08-03 | 0001104659-26-082905 | | 2026-07-06 | 09:13 ET | [8-K](/filings/0001104659-26-080613.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-080613 | | 2026-06-24 | 21:28 ET | [S-1](/filings/0001104659-26-076958.md) | Registration statement | 0001104659-26-076958 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037933.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1971387 - Tickers: LIMN, LIMNW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.